1.Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Takeshi CHIDA ; Kazuhito KAWATA ; Kazuyoshi OHTA ; Erika MATSUNAGA ; Jun ITO ; Shin SHIMOYAMA ; Satoru YAMAZAKI ; Hidenao NORITAKE ; Tetsuro SUZUKI ; Takafumi SUDA ; Yoshimasa KOBAYASHI
Gut and Liver 2018;12(2):201-207
BACKGROUND/AIMS: Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated. METHODS: Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV). RESULTS: Total, LDL−, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL− and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels. CONCLUSIONS: Clearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.
Apolipoprotein A-I
;
Apolipoprotein A-II
;
Apolipoprotein C-II
;
Apolipoprotein C-III
;
Apolipoproteins
;
Apolipoproteins B
;
Apolipoproteins E
;
Cholesterol
;
Genotype
;
Hepacivirus*
;
Hepatitis C*
;
Hepatitis*
;
Humans
;
Lipid Metabolism
;
Lipoproteins
;
Recurrence
2.Evaluating the Pilot Usability for Telenursing-based Cancer Pain Monitoring System
Shiori YOSHIDA ; Fumiko SATO ; Keita TAGAMI ; Makoto SHIMOYAMA ; Shin TAKAHASHI
Palliative Care Research 2021;16(1):99-108
The purpose of this study was to evaluate the pilot usability used in a telenursing-based cancer pain monitoring system. Health care providers and advanced cancer patients who visited a hospital as outpatients (n=10/group) used and evaluated the system using a Web Usability Scale (WUS) and free description. Of the WUS seven factors, “comprehensibility” and “content reliability” received good evaluation, and “ease of operation”, “visual effects”, “responsiveness”, “usefulness”, and “acceptablity” didn’t received good evaluation. In the free description, the system was evaluated to enhance self-management of cancer pain, a request for expansion of operation, and social issues were shown. Improving patient usability is an issue, and sufficient orientation is required to verify the effects.